Eli Lil­ly, Boehringer In­gel­heim get ap­proval to ex­pand Jar­diance, Syn­jardy la­bels to kids with type 2 di­a­betes

3 years ago
Pharma
FDA+

No­vo Nordisk sues unau­tho­rized semaglu­tide com­pounders, tem­pers ex­pec­ta­tions for We­govy's glob­al roll­out

3 years ago
Pharma
Marketing

Tri­bunal dis­miss­es Boehringer In­gel­heim's li­a­bil­i­ty claim against Sanofi in Zan­tac case

3 years ago
Pharma
Law

Bi­par­ti­san bill seeks to tight­en the do­mes­tic phar­ma sup­ply chain

3 years ago
Pharma
Manufacturing

Q&A with Genen­tech CEO Alexan­der Hardy on Medicare's drug price ne­go­ti­a­tions

3 years ago
People
Law

Mar­ket­ingRx roundup: Eli Lil­ly’s mar­ket­ing chief at Cannes Li­ons, Bio­gen rais­es more Alzheimer’s aware­ness

3 years ago
Pharma
Marketing

Bris­tol My­ers joins the le­gal fight over in­com­ing Medicare drug price ne­go­ti­a­tions

3 years ago
Law

Phar­ma big win­ners at Cannes ad fes­ti­val in­clude Hori­zon, As­traZeneca, Eli Lil­ly and AS­CO: #Can­nes­Lions2023

3 years ago
Pharma
Marketing

Pfiz­er flex­es its cre­ative trans­for­ma­tion at Cannes ad fes­ti­val: #Can­nes­Lions2023

3 years ago
Pharma
Marketing

Bay­er, GSK's Vi­iV among health and well­ness win­ners at Cannes cre­ativ­i­ty fes­ti­val: #Can­nes­Lions2023

3 years ago
Pharma
Marketing

Swiss biotech un­loads US rights to Duchenne can­di­date for $231M

3 years ago
Deals

Up­dat­ed: FDA ap­proves an­ti-in­flam­ma­to­ry drug Lodoco to treat car­dio­vas­cu­lar dis­ease

3 years ago
FDA+

UniQure reach­es mile­stone, Idor­si­a's bridge fi­nanc­ing ex­tends run­way, and Phar­varis scores $70M place­ment

3 years ago
Financing

As­traZeneca pon­ders a Chi­na phar­ma spin­off to pro­tect it­self from geopo­lit­i­cal fall­out — FT

3 years ago
China
Pharma

De­nali claims a neu­ro­fil­a­ment vic­to­ry in Hunter syn­drome, two years af­ter let­ting down Wall Street

3 years ago
R&D

Fra­zier and Ala­mar Bio­sciences cre­ate im­mune and can­cer biotech At­tovia with $60M in fund­ing

3 years ago
Financing
Startups

Lil­ly inks $2.4B cash deal to buy DICE and its im­munol­o­gy pipeline

3 years ago
Deals
R&D

Bavar­i­an Nordic's pur­chase of Emer­gen­t's late-stage Chikun­gun­ya vac­cine pays off in PhI­II read­out

3 years ago
R&D

Ar­cel­lx's cell ther­a­py is on hold af­ter pa­tient death in mul­ti­ple myelo­ma tri­al

3 years ago
R&D
Cell/Gene Tx

The End­points 11 is back: Nom­i­nate your fa­vorite biotech for our an­nu­al re­port on the most promis­ing star­tups in the ...

3 years ago
Bioregnum

As­traZeneca scraps oral GLP-1 af­ter PhI ‘does not meet that am­bi­tion’ of trump­ing the com­pe­ti­tion

3 years ago
R&D
Pharma

F2G gets re­ject­ed by the FDA, which wants more da­ta be­fore it will ap­prove an­ti­fun­gal drug, com­pa­ny says

3 years ago
R&D
FDA+

Mol­e­c­u­lar Tem­plates cuts more staff just months af­ter let­ting go half of work­force

3 years ago
Financing

Rhythm’s Im­civree shows off con­tin­ued BMI de­crease in rare obe­si­ty con­di­tion

3 years ago
R&D
First page Previous page 324325326327328329330 Next page Last page
A service from the Financial Times